Entera Bio

Entera Bio

Yahoo Finance • 8 days ago

Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors

Entera Bio Ltd. Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN) He joins Entera with two decades of clinical development, regulatory execution, and women's h... Full story

Yahoo Finance • 16 days ago

Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors

Mr. Germano brings more than 35 years of biopharmaceutical leadership experience, including as Group President of Pfizer's Global Innovative Pharmaceutical business Extensive public company board experience, including current service as Ch... Full story

Yahoo Finance • 3 months ago

Entera Bio shares slip as Q2 loss comes in wider than expected

Medical research testing ©rawpixel Entera Bio Ltd. (NASDAQ:ENTX) shares fell 1.05% in pre-market trading after the clinical-stage biotechnology company reported a larger-than-expected second-quarter loss as spending increased ahead of a p... Full story

Yahoo Finance • 3 months ago

Entera Q2 Loss Widens, FDA Backs EB613 For Phase 3 Osteoporosis Trial, Expects Data In Q2 Of FY28

(RTTNews) - Entera Bio Ltd. (ENTX), a clinical-stage biopharmaceutical company, reported a wider net loss for the second quarter, on surge in financial expense and more than double the growth in research and development expenses. Further,... Full story

Yahoo Finance • 3 months ago

Entera Announces Second Quarter 2026 Financial Results and Business Updates

U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis Oversubscribed $275 Million Pri... Full story

Yahoo Finance • 3 months ago

Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

TEL AVIV, July 31, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company’s Chief Executive Officer, Miranda Toledano, will be p... Full story

Yahoo Finance • 3 months ago

Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired

(RTTNews) - Today's top biotech gainers include Entera Bio, following an oversubscribed private placement financing; Gossamer, which is progressing toward a planned Seralutinib NDA submission in September; First Tracks, which has been firi... Full story

Yahoo Finance • 4 months ago

Top Biotech Gainers: CDNA Soars On Medicare Policy, ATAI Acquired, ABT Lifts Outlook, APLM On Watch

(RTTNews) - Today's top gainers in the biotech space include CareDx, which rallied after Medicare finalized its Local Coverage Determination process for molecular testing of solid organ allograft rejection; AtaiBeckley, after agreeing to b... Full story

Yahoo Finance • 4 months ago

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera’s plan to submit a New Drug Application (NDA) for EB61... Full story

Yahoo Finance • 5 months ago

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

EB612, a first-in-class long-acting PTH(1-34) oral peptide  for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026 EB618, a first-in-class d... Full story

Yahoo Finance • 5 months ago

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

Entera Bio Ltd. The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 Single tablet EB613 achieved a comparable... Full story

Yahoo Finance • 6 months ago

Entera Bio GAAP EPS of -$0.07 beats by $0.02

* Entera Bio press release [https://seekingalpha.com/pr/20508125-entera-announces-first-quarter-2026-financial-results-and-updates-across-its-oral-peptide] (ENTX [https://seekingalpha.com/symbol/ENTX]): Q1 GAAP EPS of -$0.07 beats by $0.... Full story

Yahoo Finance • 6 months ago

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted to ENDO2026 and ASBMR EB612, the first... Full story

Yahoo Finance • 7 months ago

Entera Bio prices $10M direct investment, sees up to $24.5M in total proceeds

* Entera Bio (ENTX [https://seekingalpha.com/symbol/ENTX]) said [https://seekingalpha.com/pr/20460875-entera-bio-announces-pricing-of-10_0-million-direct-investment-by-bvf-partners-with-potential] on Thursday it had entered into a securi... Full story

Yahoo Finance • 7 months ago

Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates

EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with comments expected in early Q2 2026 EB612, th... Full story

Yahoo Finance • 8 months ago

Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis

Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 as Phase 3 candidate, following succe... Full story

Yahoo Finance • 9 months ago

Opko Health (OPK) Expands Entera Partnership for Drug Co-Development

Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $3 to invest in. On February 4, Opko Health Inc. (NASDAQ:OPK) announced it expanded its partnership with Entera Bio Ltd., a company developing oral peptide and protein replaceme... Full story

Yahoo Finance • 12 months ago

Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference

JERUSALEM, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies, today announced that the Company’s Chief Executive Of... Full story

Yahoo Finance • 12 months ago

Entera Bio GAAP EPS of $0.07

* Entera Bio press release [https://seekingalpha.com/pr/20308640-entera-bio-announces-third-quarter-2025-financial-results-and-business-updates] (ENTX [https://seekingalpha.com/symbol/ENTX]): Q3 GAAP EPS of $0.07. * Research and develo... Full story

Yahoo Finance • 12 months ago

Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates

FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Impact on Trabecular and Cortical Bone In... Full story